|
 |
| EXPERIMENTAL RESEARCH ARTICLE |
|
|
|
| Year : 2020 | Volume
: 52
| Issue : 2 | Page : 102-107 |
| |
SB365 induces apoptosis and suppresses proliferation of glioblastoma cells
Joo Han Lim, Kyung Hee Jung, Mi-Soon Kim, Jee Hyeon You, In-Suh Park, Soon-Sun Hong
Department of Medicine, College of Medicine, Inha University, Incheon, Republic of Korea
| Date of Submission | 18-Feb-2019 |
| Date of Decision | 13-May-2019 |
| Date of Acceptance | 14-Apr-2020 |
| Date of Web Publication | 3-Jun-2020 |
Correspondence Address:
In-Suh Park
Department of Pathology, College of Medicine, Inha University, 366 Seohae-Daero, Jung-Gu, Incheon 22332
Republic of Korea
Soon-Sun Hong
Department of Biomedical Sciences, College of Medicine, Inha University, 366 Seohae Daero, Jung Gu, Incheon 22332
Republic of Korea
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijp.IJP_117_19
CONTEXT: Glioblastoma is a malignant brain tumor with limited treatment modalities due to its nature. SB365, Pulsatilla saponin D, is known to induce apoptosis and inhibit the growth of many cancer cells.
AIM: We elucidated the anticancer effects of SB365 in glioblastoma cells.
METHODS: We examined the antiproliferative activity of SB365 in human glioblastoma cell lines. Apoptosis was evaluated using the Hoechst assay, TUNEL assay, DAPI nuclear staining, and Western blotting analysis. To test the antimetastatic capacity of SB365, cell migration assay was conducted, and hypoxia-inducible factor-1 alpha (HIF-1α) expression and vascular endothelial growth factor (VEGF) level were determined under hypoxic conditions.
STATICAL ANALYSIS: Significance of the results was confirmed by a one-way analysis of variance analysis.
RESULTS: SB365 treatment suppressed the growth of glioblastoma cells and resulted in apoptotic morphological features such as nuclear condensation and fragmentation, enhancing the expression of cleaved poly (ADP-ribose) polymerase and caspase-3. It also significantly delayed cell migration and decreased the HIF-1α expression and VEGF secretion.
CONCLUSION: Our findings thus demonstrate that SB365 induced apoptosis and delayed the growth and migration of human glioblastoma cells. It is considered that SB365 would be a promising therapeutic option for glioblastoma.
Keywords: Apoptosis, glioblastoma, hypoxia-inducible factor-1 alpha, SB365, vascular endothelial growth factor
How to cite this article:
Lim JH, Jung KH, Kim MS, You JH, Park IS, Hong SS. SB365 induces apoptosis and suppresses proliferation of glioblastoma cells. Indian J Pharmacol 2020;52:102-7 |
How to cite this URL:
Lim JH, Jung KH, Kim MS, You JH, Park IS, Hong SS. SB365 induces apoptosis and suppresses proliferation of glioblastoma cells. Indian J Pharmacol [serial online] 2020 [cited 2023 Dec 9];52:102-7. Available from: https://www.ijp-online.com/text.asp?2020/52/2/102/285723 |
FNx01These authors equally contributed
| » Introduction | |  |
Glioblastoma is known as the most aggressive brain tumors, about 45.6% of central nervous system malignant tumors.[1] After the temozolomide era, temozolomide plus radiation increased the median survival of the patients,[2] and consecutive clinical trials have been conducted to increase the survival of patients with glioblastoma, but the median survival is still 15–16 months.[3]
The poor survival is partially due to the nature of glioblastoma. The location of the tumor hinders the delivery of chemotherapeutic agents, and only small or lipophilic molecules can access the tumor across the blood–brain barrier.[4] In addition, the hypoxic microenvironment also contributes to the invasive phenotype. Hypoxic niches overexpress hypoxia-inducible factor 1 (HIF-1), which promotes the mesenchymal shift of cells and enhances their migration.[5],[6] In addition, angiogenic factors such as vascular endothelial growth factor (VEGF) increase microvascular permeability and facilitate metastasis.[7] To overcome these angiogenic features of the tumor, clinical trials have targeted the VEGF signaling pathway.[7]
Traditional natural compounds can provide interesting therapeutic alternatives. Over the past few decades, numerous traditional natural compounds have been reported to induce apoptosis of cancer cells in preclinical studies.[8] Among them, Pulsatilla koreana, a hairy, tufted, perennial herb, is used as a traditional Korean herbal medicine.[9] It contains several medically active constituents including saponin D (hereafter called SB365) which has antitumor activities with antiangiogenesis.[10]
Therefore, we studied the anticancer activity of SB365 in glioblastoma cells.
| » Methods | | |
Cell proliferation assay
Human glioblastoma cells (U87MG, A172, and T98G) were cultured in DMEM (Dulbecco's Modified Eagle's Medium) containing 10% fetal bovine serum and 1% antibiotics (Invitrogen, Carlsbad, CA, USA). The cells were seeded and then incubated overnight, and SB365 was added for 72 h at 37°C. 0.5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) in fresh media was incubated for 4 h, followed by dimethyl sulfoxide (DMSO) addition. The optical density of each well was then read at 540 nm. The reduction in cell viability was expressed as percentage compared with DMSO alone.
Assessment of apoptotic morphology
The adherent cells were fixed with paraformaldehyde after SB365 treatment, followed by staining with Hoechst 33258 at 37°C for 30 min. They were observed under a fluorescence microscopy at ×400 magnification.
DAPI and TUNEL staining assay
Cells were seeded into a cover glass and treated with 10 μM SB365 for 24 h, and fixed in paraformaldehyde, and stained with 4',6-diamidino-2-phenylindole (DAPI)(2 μg/ml). The cells were observed for fluorescent nuclear fragmentations, and TUNEL staining was performed.
Wound migration assay
The cells were seeded, and a linear wound was made at 90% confluency using a 200-μl pipette tip. After washing with Dulbecco's Phosphate-Buffered Saline (DPBS), the monolayer was treated with SB365 for 24 h. They were washed and fixed in methanol, and the migrated cells were measured by magnifying ×40 under a phase-contrast microscope.
ELISA assay
To determine the VEGF proteins secreted into the media, the plates were coated with anti-VEGF antibody and were incubated with 1% bovine serum albumin. Conditioned media were incubated for 2 h with biotinylated anti-VEGF antibody, and the plates were embedded with horseradish peroxidase (HRP)-conjugated streptavidin for 30 min. After adding 2N H2 SO4, the absorbance was determined by a microplate reader at 450 nm.
Western blotting
The cells were lysed using : Radioimmunoprecipitation assay buffer (RIPA), and the proteins were separated by 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis and incubated with the primary antibodies such as HIF-1, cleaved poly (ADP-ribose) polymerase (PARP), cleaved caspase-3, and actin. After the incubation with subsequent secondary antibodies, the bands were detected using the enhanced chemiluminescence plus system (Amersham Biosciences).
Statistical methods
SPSS software (version 10.0: SPSS, Chicago, IL, USA) for Windows was applied for statistical analysis, and all bar graphs were expressed as the means and standard deviation.
| » Results | | |
Cell growth
After glioblastoma cells (U87MG, A172, and T98G) were exposed to indicated concentrations of SB365, the anticancer effect of SB365 was determined with MTT assay. SB365 inhibited the cell growth dose dependently in glioblastoma cells [Figure 1]. | Figure 1: Effect of SB365 on human glioblastoma cell proliferation. U87MG, A172, and T98G cells were seeded and incubated for 24 h in 96-well plates, and then, the cells were treated with SB365 (1–20 μM) for 72 h, and cell viability was evaluated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Data are represented as the mean ± standard deviation from triplicate wells
Click here to view |
Apoptosis of glioblastoma cells
In DAPI staining, SB365-treated cells showed apoptosis-typical changes including fragmented and condensed nuclei [Figure 2]a. The phenomena were confirmed by TUNEL staining for DNA fragmentation [Figure 2]b. Moreover, Western blotting analysis showed the increase of cleaved PARP and cleaved caspase-3 in a dose-dependent manner [Figure 2]c. From staining with Hoechst 33258 under fluorescence microscope, control cells showed round nuclei, whereas apoptotic cells were increased after SB365 treatment, displaying perinuclear apoptotic bodies and bright nuclear condensation [Figure 3]. | Figure 2: Effect of SB365 on apoptosis in glioblastoma cells. (a and b) The induction of apoptosis by SB365 treatment was examined by DAPI and TUNEL staining, followed by imaging at ×400 magnification. Arrows indicate morphological features of apoptotic cells, such as fragmented and condensed nuclei in SB365-treated cells. (c) The expression of cleaved caspase-3 and cleaved poly (ADP-ribose) polymerase was determined by Western blotting in SB365-treated cells at the indicated doses for 72 h
Click here to view |
 | Figure 3: Apoptotic morphology after SB365 treatment in glioblastoma cells. Cells were stained with the Hoechst 33342 DNA-binding fluorescent dye after SB365 treatment for 72 h. In morphological analysis, SB365-induced apoptosis recognized as nuclear chromatin condensation and fragmentation in U87MG and A172 glioblastoma cells. Data are represented as the mean ± standard deviation from three independent experiments ×400 magnification. *P < 0.05 and ***P < 0.001 versus control group
Click here to view |
Migration and invasion of glioblastoma cells
To assess the antimetastatic property of SB365, migration assay was performed using glioblastoma cells. U87MG and A172 cells were exposed to various SB365 doses for 24 h. As a result, the control group showed high migration to the wound area, whereas SB365 significantly suppressed cell migration [Figure 4]. | Figure 4: Effect of SB365 on glioblastoma cell migration. (a and b) Representative images of migration assay in U87MG and A172 cells after the treatment with SB365 (1-20 μM) for 24 h. For quantification, we analyzed the migrated cells at the indicated dose of SB365. All images were captured at ×200 magnification. Data are represented as the mean ± standard deviation from triplicate experiments. *P < 0.05, **P < 0.01 and ***P < 0.001 versus control group
Click here to view |
Hypoxia-inducible factor-1 alpha and vascular endothelial growth factor expression
When the A172 glioblastoma cells were treated with SB365 in hypoxia-mimicking condition, the upregulated HIF-1α expression was blocked in the glioblastoma cells [Figure 5]a. In the ELISA study to measure VEGF secretion, SB365 suppressed the increased VEGF secretion in a dose-dependent manner [Figure 5]b. | Figure 5: Effect of SB365 on hypoxia-inducible factor-1 alpha expression under hypoxia. (a) Expression of hypoxia-inducible factor-1 alpha by SB365 was observed in hypoxia-induced A172 glioblastoma cells. (b) Production of vascular endothelial growth factor by SB365 was determined using sandwich ELISA in hypoxia-induced A172 cells for 24 h (CoCl2, 100 μM). Data from the triplicate wells are represented as mean ± standard deviation.###P < 0.001 versus control group; **P < 0.01 and ***P < 0.001 versus CoCl2 group
Click here to view |
| » Discussion | | |
Despite advances in treatment modalities, glioblastoma still remains an incurable disease. Due to the nature of glioblastoma, angiogenesis has emerged as a major target for drug development against glioblastoma over the past decade. Bevacizumab got accelerated approval for recurrent glioblastoma in the United States, and its combination with irinotecan showed effective outcomes in a clinical study.[11] Other anti-VEGF inhibitors have also shown promising outcomes in preclinical studies.[12] However, in a recent REGAL trial, an oral pan-VEGF RTK inhibitor did not improve survival outcomes in recurrent glioblastoma patients compared to lomustine.[7] The CENTRIC EORTC 26071–22072 study also reported that the combination of cilengitide and temozolomide did not prolong survival outcomes in newly diagnosed glioblastoma patients.[13] Other randomized Phase II clinical trials have also shown that anti-VEGF agents did not show any clinical benefits.[14],[15] Therefore, further studies are needed to overcome the limitations of current treatment modalities.
Natural products have several advantages as anticancer agents. They have relatively tolerable side effects and synergistic effects with cytotoxic chemotherapy.[16] Particularly, natural products such as curcumin and ginger have shown promising anticancer effects in various cancer cell lines.[17],[18] In the past, the dissonance of medicines from natural compounds was a time-consuming procedure. However, finding active compounds from plants has now been accelerated by modern techniques. Therefore, great efforts are underway to discover active natural compounds in order to treat cancer.[17]
SB365 has been shown to exhibit its antitumor effects through apoptosis and antiangiogenesis in hepatocellular carcinoma, pancreatic cancer, and colon cancer.[19],[20],[21] In this study, the growth of glioblastoma cells was suppressed by SB365 treatment by 40%–70%. Our results also show that apoptosis, evident by Hoechst staining, DAPI staining, and TUNEL assay, was observed in SB365-treated glioblastoma cells.[22] In addition, apoptosis by SB365 was reconfirmed by the increase in cleaved PARP and caspase-3 levels.
Hypoxia-induced necrosis and neovascularization are also major pathognomonic features of glioblastoma. The hypoxic condition in glioblastoma activates the expression of genes such as HIFs and VEGF, which promote more aggressive phenotypes such as tumor growth, angiogenesis, migration, and metastasis.[23],[24] In particular, inhibition of HIF-1α may induce apoptosis and prevent tumor progression.[24] Here, SB365 inhibited the migration of glioblastoma cells and the HIF-1α expression and VEGF secretion, which are clearly alike to previous literatures that SB365 reduced angiogenesis.[19],[20],[21]
Our study has some limitations. First, it was conductedin vitro in cell lines, and further,in vivo study is necessary to confirm these results. However, to our knowledge, this is the first report, indicating that SB365 has an anticancer effect in glioblastoma cells.
| » Conclusion | | |
SB365 demonstrates anticancer activity against glioblastoma cells by apoptosis and antiangiogenesis suppressing cell growth. These findings indicate that SB365 could be a good natural candidate for the therapy of brain tumors.
Acknowledgments
We would like to thank a grant from Inha University, South Korea.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
| » References | | |
| 1. | Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol 2014;16 Suppl 4:iv1-63.  |
| 2. | Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl Med 2005;352:987-96. |
| 3. | Bi WL, Beroukhim R. Beating the odds: Extreme long-term survival with glioblastoma. Neuro Oncol 2014;16:1159-60. |
| 4. | Wei X, Chen X, Ying M, Lu W. Brain tumor-targeted drug delivery strategies. Acta Pharm Sin B 2014;4:193-201. |
| 5. | Joseph JV, Conroy S, Pavlov K, Sontakke P, Tomar T, Eggens-Meijer E, et al. Hypoxia enhances migration and invasion in glioblastoma by promoting a mesenchymal shift mediated by the HIF1α-ZEB1 axis. Cancer Lett 2015;359:107-16. |
| 6. | Rong Y, Durden DL, Van Meir EG, Brat DJ. 'Pseudopalisading' necrosis in glioblastoma: A familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol 2006;65:529-39. |
| 7. | Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 2013;31:3212-8. |
| 8. | He YC, Zhou FL, Shen Y, Liao DF, Cao D. Apoptotic death of cancer stem cells for cancer therapy. Int J Mol Sci 2014;15:8335-51. |
| 9. | Bang SC, Lee JH, Song GY, Kim DH, Yoon MY, Ahn BZ. Antitumor activity of Pulsatilla koreana saponins and their structure-activity relationship. Chem Pharm Bull (Tokyo) 2005;53:1451-4. |
| 10. | Hong SW, Jung KH, Lee HS, Son MK, Yan HH, Kang NS, et al. SB365, Pulsatilla saponin D, targets c-Met and exerts antiangiogenic and antitumor activities. Carcinogenesis 2013;34:2156-69. |
| 11. | Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-40. |
| 12. | Pham K, Luo D, Siemann DW, Law BK, Reynolds BA, Hothi P, et al. VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner. Cancer Lett 2015;360:60-7. |
| 13. | Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2014;15:1100-8. |
| 14. | Lee EQ, Kaley TJ, Duda DG, Schiff D, Lassman AB, Wong ET, et al. A Multicenter, Phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma patients. Clin Cancer Res 2015;21:3610-8. |
| 15. | Peereboom DM, Ahluwalia MS, Ye X, Supko JG, Hilderbrand SL, Phuphanich S, et al. NABTT 0502: A phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. Neuro Oncol 2013;15:490-6. |
| 16. | Kanai M, Yoshimura K, Asada M, Imaizumi A, Suzuki C, Matsumoto S, et al. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol 2011;68:157-64. |
| 17. | Safarzadeh E, Sandoghchian Shotorbani S, Baradaran B. Herbal medicine as inducers of apoptosis in cancer treatment. Adv Pharm Bull 2014;4:421-7. |
| 18. | Kanai M. Therapeutic applications of curcumin for patients with pancreatic cancer. World J Gastroenterol 2014;20:9384-91. |
| 19. | Hong SW, Jung KH, Lee HS, Choi MJ, Son MK, Zheng HM, et al. SB365 inhibits angiogenesis and induces apoptosis of hepatocellular carcinoma through modulation of PI3K/Akt/mTOR signaling pathway. Cancer Sci 2012;103:1929-37. |
| 20. | Son MK, Jung KH, Lee HS, Lee H, Kim SJ, Yan HH, et al. SB365, Pulsatilla saponin D suppresses proliferation and induces apoptosis of pancreatic cancer cells. Oncol Rep 2013;30:801-8. |
| 21. | Son MK, Jung KH, Hong SW, Lee HS, Zheng HM, Choi MJ, et al. SB365, Pulsatilla saponin D suppresses the proliferation of human colon cancer cells and induces apoptosis by modulating the AKT/mTOR signalling pathway. Food Chem 2013;136:26-33. |
| 22. | Elmore S. Apoptosis: A review of programmed cell death. J Toxicol Pathol 2007;35:495-516. |
| 23. | Evans SM, Judy KD, Dunphy I, Jenkins WT, Hwang WT, Nelson PT, et al. Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res 2004;10:8177-84. |
| 24. | Melillo G. Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol Cancer Res 2006;4:601-5. |
[Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5]
| This article has been cited by | | 1 |
PATZ1 Induces Apoptosis through PUMA in Glioblastoma |
|
| Xiang Tao, Ge Zhang, Junhui Liu, Baowei Ji, Haitao Xu, Zhibiao Chen, Xueliang Wu | | Journal of Oncology. 2022; 2022: 1 | | [Pubmed] | [DOI] | |
|
|
|
|
